Not available
Quote | Cellectis S.A. (NASDAQ:CLLS)
Last: | $3.19 |
---|---|
Change Percent: | -2.1% |
Open: | $2.92 |
Close: | $3.19 |
High: | $3.25 |
Low: | $2.9 |
Volume: | 396,495 |
Last Trade Date Time: | 11/28/2023 03:00:00 am |
News | Cellectis S.A. (NASDAQ:CLLS)
NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold a general meeting on December 22,...
2023-11-15 09:50:09 ET DENVER, Colo., Nov. 15, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; SciSparc Ltd (NASDAQ: SPRC), Chemomab Therapeutics Ltd (NASDAQ: CMMB), Cellectis SA (NASDAQ: CLLS), AstraZene...
Message Board Posts | Cellectis S.A. (NASDAQ:CLLS)
Subject | By | Source | When |
---|---|---|---|
https://ih.advfn.com/stock-market/NASDAQ/cellectis-$CLLS/stock-news/83912184/cell | Frankestin | investorshub | 01/10/2023 5:27:59 PM |
Cellectis Announces Positive Preliminary Clinical Data for UCART22 | Frankestin | investorshub | 12/14/2022 8:39:18 AM |
will there be something interesting? | Frankestin | investorshub | 11/01/2022 10:53:45 AM |
also interesting here! | Frankestin | investorshub | 06/01/2022 5:10:36 PM |
News: $CLLS Cellectis and Lonza Enter cGMP Manufacturing | whytestocks | investorshub | 10/01/2019 8:40:21 PM |
News, Short Squeeze, Breakout and More Instantly...
Cellectis S.A. Company Name:
CLLS Stock Symbol:
NASDAQ Market:
NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold a general meeting on December 22,...
2023-11-15 09:50:09 ET DENVER, Colo., Nov. 15, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; SciSparc Ltd (NASDAQ: SPRC), Chemomab Therapeutics Ltd (NASDAQ: CMMB), Cellectis SA (NASDAQ: CLLS), AstraZene...
Execution of binding subsequent investment agreement regarding contemplated additional equity investment of $140M by AstraZeneca, previously anno...